Therefore, utilization of cardio‐protective agent that target AMPK‐SIRT3 axis is supposed to be a novel therapeutic strategy to ameliorate ATO‐induced cardiac hypertrophy. Here, SIRT3 is linked to cardiac hypertrophy.